anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 223,531-223,560
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

223,531-223,560 of 303,780

filter-aware
06
Uses a process diagram to illustrate the transition from cold to hot tumor states via viral infection.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The central diagram shows a biological mechanism comparing 'Absence of Effector T Cells' (Platinum resistant) vs 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
The slide uses a timeline to establish market maturity and investor confidence.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
10
The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
Waterfall plot and spider plot showing patient-level clinical outcomes.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
Kaplan-Meier survival curve showing superior performance of VIRO-15 compared to historical 4th line treatment data.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
The chart compares cross-trial data; the footnote explicitly warns against direct comparison due to protocol differences.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) as evidence of efficacy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide highlights a strategic partnership, funding, and commercial rights split between US and Greater China markets.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
The slide highlights a combination therapy approach involving oncolytic immunotherapy and adoptive cell therapy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a map of the US as a background to anchor the market sizing to a specific geography.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
25
The slide highlights physical assets and operational capacity.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
26
The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
27
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies, emphasizing non-GMO status and GLP tox readiness.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The slide highlights key defensive moats including patent counts, expiration dates, and lack of royalty obligations.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
29
The slide uses a grid layout to categorize team members into three distinct groups: Executive Team, Board of Directors, and Operations & R&D.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
30
The slide uses a combination of a checklist for past achievements and a timeline arrow for future goals.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
31
Includes footnotes regarding market close date and specific financing obligations.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
32
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide indicates this is an appendix section of an October 2023 corporate presentation.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide lists key advisors, some of whom also hold executive roles (CEO, CMO, CFO) within the company.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
The slide compares pre- and post-treatment biopsies for three patients (15A-16, 15A-18, 15A-23) using both visual microscopy and quantitative infiltration histograms.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
The slide uses a combination of a bar chart (ELISPOT data) and a line chart (SLD over time) to show clinical efficacy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
38
The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit